高级检索
当前位置: 首页 > 详情页

Surgical treatment of small-cell lung cancer: long-term prognosis and patterns of adjuvant therapy

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. [2]Medical Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain. [3]Department of Thoracic Surgery, Chengdu Shang Jin Nan Fu Hospital, Chengdu, China.
出处:
ISSN:

关键词: Small-cell lung cancer (SCLC) surgical intervention perioperative adjuvant therapy overall survival (OS) disease-free survival (DFS)

摘要:
Small-cell lung cancer (SCLC) is a highly aggressive malignancy predominantly treated with chemotherapy or chemoradiotherapy. The role of surgical intervention in SCLC, however, remains inadequately defined. This study aimed to retrospectively analyze the clinical data of patients with SCLC who underwent surgical treatment to assess the impact of surgery combined with perioperative adjuvant therapy on long-term prognosis, with the goal of informing future treatment strategies.This study included patients with SCLC who underwent surgical treatment at West China Hospital, Sichuan University, between 2005 and 2021. Prognostic factors influencing overall survival (OS) and disease-free survival (DFS) were analyzed using univariate and multivariate Cox regression models, in conjunction with the Kaplan-Meier method.A cohort of 121 patients with SCLC who underwent surgical treatment was included. Multivariate Cox regression analysis indicated that postoperative adjuvant chemotherapy [hazard ratio (HR) =0.45; 95% confidence interval (CI): 0.24-0.85] was significantly associated with improved OS, whereas a smoking index exceeding 400 (HR =1.0011; 95% CI: 1.0004-1.0018) was identified as an independent adverse prognostic factor. Pathological stratification showed that prophylactic cranial irradiation (PCI) was significantly associated with improved OS in stage II/III patients (P<0.05) but had not in stage I patients (P>0.05). Regarding DFS, preoperative neoadjuvant chemotherapy was associated with significantly prolonged DFS (HR =0.44; 95% CI: 0.21-0.94), while lymph node metastasis was identified as a negative predictor (HR =1.97; 95% CI: 1.16-3.36).Surgical intervention combined with perioperative adjuvant therapy provides significant survival benefits for patients with SCLC. Notably, preoperative neoadjuvant chemotherapy and postoperative adjuvant chemotherapy were associated with prolonged DFS and OS. For early-stage patients, the application of PCI should be approached cautiously. Further prospective studies are warranted to better balance its potential risks and benefits.Copyright © 2025 AME Publishing Company. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
第一作者:
第一作者机构: [1]Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
共同第一作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65780 今日访问量:0 总访问量:5151 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号